Grail

E158: Global trade disrupted, Adobe/Figma canceled, realtors sued, Trump blocked

All-In Podcast

Makes a leading test for free DNA cancer detection. Its merger with Illumina was forced to unwind due to regulatory issues.

#121 – Azra Raza, M.D.: Why we’re losing the war on cancer

Peter Attia MD

A company in the Bay Area developing similar liquid biopsy technologies to detect multiple cancers from a single blood sample, currently in Phase 2 trials.

Dr. Peter Attia — Longevity Drugs, Alzheimer's Disease, and More

Tim Ferriss

A company pioneering liquid biopsies using cell-free DNA for early cancer detection, later acquired by Illumina. Its method focuses on analyzing methylation patterns in cell-free DNA.

#06 – D.A. Wallach: music, medicine, longevity, and disruptive technologies

Peter Attia MD

A spin-out of Illumina that uses deep sequencing of peripheral blood to detect early cancers by identifying tumor DNA.

Tim O'Reilly Interview | The Tim Ferriss Show (Podcast)

Tim Ferriss

A company working to develop an early detection test for cancer, used as an example of an organization pursuing a hard, impactful problem rather than just financial gain.

Peter Diamandis and Tony Robbins on strategies that promote longevity now – and in the near future

FoundMyFitness

A liquid biopsy test that can detect DNA from 50 different cancers in the bloodstream.

290 ‒ Liquid biopsies for early cancer detection, the role of epigenetics in aging, and the more

Peter Attia MD

213 ‒ Liquid biopsies and cancer detection | Max Diehn, M.D. Ph.D.

Peter Attia MD

A diagnostic company using methylation patterns of cell-free DNA for pan-cancer screening, still in the CLIA environment and not FDA approved for screening.

Outlive: The Science and Art of Longevity — Dr. Peter Attia

Tim Ferriss

A company (now owned by Illumina) that developed a liquid biopsy test using cell-free DNA to screen for cancer, assessing its presence and origin by looking at methylation patterns.